araag2/HINT huggingface dataset:
Clinical trial NCT00101894 (phase 1, status: completed)
Conditions: rectal cancer, colon cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3
Drugs: folfox-4, amg 706, folfiri
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC1(C)CNC2=C1C=CC(=C2)N=C(O)C1=C(NCC2=CC=NC=C2)N=CC=C1, FC1=CNC(=O)NC1=O
Eligibility criteria:

        For complete inclusion and exclusion criteria, please refer to the investigator. Inclusion
        Criteria

          1. Competent to comprehend, sign, and date an Institutional Review Board (IRB) approved
             informed consent form

          2. Diagnosis of metastatic colorectal adenocarcinoma (may have received 1 prior
             chemotherapy regimen for metastatic CRC)

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          4. Adequate hematological function

          5. Adequate renal function

          6. Adequate hepatic function

          7. Life expectancy of greater than or equal to 3 months as documented by the investigator

        Exclusion Criteria:

          1. More than 1 prior chemotherapy regimen for metastatic CRC

          2. Central nervous system (CNS) metastases

          3. History of venous thrombosis

          4. Myocardial infarction, cerebrovascular accident, transient ischemic attack, grade 2 or
             greater peripheral vascular disease, congestive heart failure, ongoing arrhythmias
             requiring medication, or unstable angina within 1 year before study enrollment

          5. History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial
             pneumonitis or pulmonary fibrosis on screening chest computed tomograph (CT) scan

          6. Average systolic blood pressure > 150mm Hg or average diastolic blood pressure of >
             90mm Hg

          7. Radiotherapy within 28 days of study enrollment or within 14 days of study enrollment
             for peripheral lesions

          8. Prior AMG 706, oral inhibitors of AMG706, panitumumab, or another anti-EGFr monoclonal
             antibody (mAb) (e.g., cetuximab [Erbitux®] or EMD 72000)

          9. Systemic chemotherapy within 28 days before study enrollment

         10. Major surgery within 28 days or minor surgery within 7days of study enrollment

         11. History of life threatening ventricular arrhythmia (eg, sustained ventricular
             tachycardia)

         12. Female and male subjects of childbearing potential not using adequate contraceptive
             precautions

         13. Participation in therapeutic clinical trials within 30 days before study enrollment

         14. Not recovered from all previous therapies

         15. Clinically significant open would, ulcer or fracture

         16. Any co-morbid medical condition that would increase the risk of toxicity
Clinical trial NCT00703261 (phase 1, status: completed)
Conditions: atherosclerotic vascular disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: atorvastatin, placebo
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or Female ages 30 to 80

          -  Participant is on a low dose statin for at least 6 weeks prior to screening or is
             statin-naive at screening

        Exclusion Criteria:

          -  Participant has human immunodeficiency virus (HIV), Hepatitis B or C

          -  Participant uses illegal drugs

          -  Participant has Type I diabetes

          -  Participant has a history of claustrophobia
Clinical trial NCT01350960 (phase 1, status: terminated)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: spc5001, saline 0.9%, spc5001, spc5001, spc5001, spc5001
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          1. Healthy male or female subjects and subjects with heterozygous Familial
             Hypercholesterolemia

               -  Healthy male or female subjects, age 18 to 65 years, inclusive will be enrolled
                  in Cohorts 1 through 4.

               -  In Cohort 5, male or female subjects with heterozygous Familial
                  Hypercholesterolemia, confirmed through genetic testing, without a history of
                  cardiovascular disease (e.g. coronary artery, peripheral artery or
                  cerebrovascular disease), hypertension or diabetes mellitus age 18-45 years,
                  inclusive, will be enrolled.

          2. BMI of 18-33 kg/m2

          3. Screening hematology, clinical chemistries, coagulation and urinalysis consistent with
             overall good health and the following criteria are met:

               -  LDL ≥.3.24 mmol/L (≥ 100 mg/dL)

               -  Triglycerides (fasted) < 4.5 mmol/L (< 398 mg/dL)

               -  ALT within normal limits for healthy subjects and ALT < 2 x ULN for FH subjects

        Exclusion Criteria:

          1. Any uncontrolled or active major systemic disease including, but not limited to:
             cardiovascular, pulmonary, gastrointestinal, metabolic, urogenital, neurological,
             immunological, psychiatric, or neoplastic disorder with metastatic potential

             - History or presence of malignancy within the past year is an exclusion criterion.
             Subjects who have been successfully treated with no recurrence of basal cell carcinoma
             of the skin or carcinoma in-situ of the cervix may be enrolled.

          2. Active acute or chronic infection, including, but not limited to: upper airway
             infection, urinary tract infection, and skin infection

          3. Use of prescription medication within 14 days prior to the planned first drug
             administration and throughout the study. For the FH subjects statin therapy (and other
             lipid lowering therapies) will be prohibited within 4 weeks prior to the first study
             drug administration.

          4. Use of non-prescription or over-the-counter medications is prohibited within 7 days
             prior to the planned first drug administration and throughout the study. This includes
             all vitamins, herbal supplements, or remedies. An exception can be made for medication
             or supplements that in the opinion of both the investigator and the Sponsor do not
             complicate or compromise the study or interfere with the study objectives.

          5. Positive results on the following Screening laboratory tests: urine or serum pregnancy
             test (women only), alcohol breath test, urine drugs of abuse, hepatitis B surface
             antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
Clinical trial NCT00437606 (phase 1, status: terminated)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: gk activator (2), ethanol
SMILES: NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O
Reason stopped: 
    poor recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-75 years of age;

          -  type 2 diabetes;

          -  normal hepatic function, or mild or moderate hepatic impairment.

        Exclusion Criteria:

          -  type 1 diabetes, or latent autoimmune diabetes in adults;

          -  diabetic neuropathy, retinopathy or nephropathy;

          -  treatment with insulin or PPAR gamma agonist within 6 weeks of screening;

          -  clinically significant cardiovascular disease.
Clinical trial NCT00609921 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: arq197
SMILES: O=C1NC(=O)[C@H]([C@@H]1C1=CNC2=CC=CC=C12)C1=CN2CCCC3=C2C1=CC=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who did not respond or are refractory to available therapy or for whom no
             standard effective systemic therapy exists.

          -  Karnofsky performance status (KPS) ≥ 70%, or Eastern Cooperative Oncology Group (ECOG)
             performance status 0 to 1

          -  Patients with adequate organ function

        Exclusion Criteria:

          -  Anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or
             investigational agents within 4 weeks prior to the first dose of ARQ 197

          -  Known symptomatic brain metastases

          -  Pregnant or breastfeeding

          -  Uncontrolled intercurrent illness
Clinical trial NCT01040637 (phase 1/phase 2, status: completed)
Conditions: healthy, opioid-induced constipation
ICD codes: Z76.3, Z76.2, F11.14, F11.181, F11.182, F11.188, F11.19, F11.24, F11.281
Drugs: td-1211, td-1211, td-1211, td-1211, td-1211, td-1211, td-1211, td-1211, td-1211, placebo
SMILES: NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, NC(=O)C1=CC=CC(=C1)[C@@H]1C[C@@H]2CC[C@H](C1)N2CCN(CC1CCCCC1)C(=O)[C@@H](O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females between 18 and 65 years of age, inclusive

          -  Healthy subjects and subjects with documented OIC on stable opioid regimen

          -  Willingness to stop all laxatives throughout the OIC screening and treatment period

        Exclusion Criteria:

          -  Any clinically significant finding in healthy subjects

          -  Have participated in another clinical trial of an investigational drug 30 days prior
             to screening

          -  History of chronic constipation prior to opioid therapy in OIC subjects

          -  Active medical disorders associated with diarrhea or intermittent loose stools in OIC
             subjects
Clinical trial NCT02279992 (early phase 1, status: terminated)
Conditions: glioma, brain neoplasms, brain metastasis
ICD codes: C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6
Drugs: vardenafil, carboplatin
SMILES: CCCC1=NC(C)=C2N1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(CC)CC1, N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    unable to accrue to the study. original pi no longer with the institute.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with recurrent malignant glioma or metastatic brain cancer requiring
             craniotomy for gross total resection, subtotal resection or biopsy

          -  Previously histopathologically proven glioma or radiographic appearance of metastatic
             lesion with a primary neoplasm that is known to metastasize to the brain

          -  Patients must have a Karnofsky performance status ≥ 60% (i.e. the patient must be able
             to care for himself/herself with occasional help from others)

          -  Patients must have normal hematologic, renal and liver function (i.e. Hemoglobin >10
             gm/dl, Absolute neutrophil count ≥ 1500/mm3, Platelets ≥ 100,000/mm3, creatinine ≤ 1.5
             mg/dl or Cr Clearance ≥ 60 mL/min, total bilirubin ≤ 1.5 mg/dl, transaminases ≤ 4
             times above the upper limits of the institutional normal.

          -  Patients must be able to provide written informed consent

        Exclusion Criteria:

          -  Patients with serious concurrent infection or medical illness, which would jeopardize
             the ability of the patient to receive the treatment outlined in this protocol with
             reasonable safety

          -  Patients who are pregnant or breast-feeding

          -  Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or
             investigational agents)

          -  Allergy to 5HT-(3) receptor antagonist including tropisetron, ondansetron

          -  Patients on enzyme-inducing anticonvulsants (Dilantin, Tegretol, Phenobarbital)

          -  Patients with unstable angina or serious cardiovascular disease

          -  Known HIV positivity or AIDS-related illness

          -  History of allergic reaction to platinum compounds or mannitol

          -  Medical conditions requiring the use of oral nitrates

          -  Patients on alpha-1 adrenergic blockers
Clinical trial NCT01337375 (phase 1, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: peginterferon alfa 2a [pegasys], peginterferon alfa-2a [pegasys], peginterferon alfa-2a [pegasys], peginterferon alfa-2a [pegasys]
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult caucasian patients, 18 - 70 years of age

          -  Hepatitis C, genotype 1

          -  Non-responder to previous anti-HCV therapy with peginterferon alfa and ribavirin

          -  Compensated liver disease (Child-Pugh class A) for >/= 24 months before baseline

          -  Positive for anti-HCV for > 6 months, with detectable serum HCV-RNA

        Exclusion Criteria:

          -  Treatment-naïve or responder to previous therapy

          -  HCV infection other than genotype 1

          -  Positive for Hepatitis A, Hepatitis B or HIV infection at screening

          -  Chronic Hepatitis of other than HCV origin

          -  Decompensated liver disease (Child-Pugh class B or C)

          -  Therapy with systemic antiviral, antineoplastic or immunomodulatory agents in the 6
             months prior to study

          -  Clinically relevant retina disorder

          -  Pregnant or lactating women and male partners of pregnant women
Clinical trial NCT00736931 (phase 1, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: brivaracetam, levetiracetam, lorazepam
SMILES: CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CC(C)CC1=CC=C(C=C1)C(C)C(O)=O, CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male or female volunteer aged 18 to 50 years inclusive

          -  Body Mass Index (BMI) between 18.0 and 30.0 kg/m² inclusive

          -  Good physical and mental health status

          -  Blood pressure and heart rate within normal range

          -  Electrocardiogram and laboratory tests without clinically significant abnormality

        Exclusion Criteria:

          -  IQ ≤ 80 as determined by Test of non-verbal intelligence

          -  Center for Epidemiological Studies Depression (CES-D Scale ≥16,

          -  Known allergy/intolerance to pyrrolidinone derivatives

          -  Abnormalities on EEG recordings

          -  Pregnant, lactating women

          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             endocrinological, neurological, psychiatric disorders

          -  Use of any hepatic enzyme-inducing drug
Clinical trial NCT01348737 (phase 1, status: completed)
Conditions: alzheimer's disease, safety, tolerability, blood concentration, healthy volunteers
ICD codes: G30.8, G30.9, G30.0, G30.1, Z71.85, Y38.4X1S, Y38.9X1S, Y38.4X1A, Y38.4X1D, Y38.5X1S, Y38.6X1S
Drugs: azd3839, azd3839 placebo
SMILES: NC1=N[C@@](C2=CC=CC(F)=C12)(C1=CC=CC(=C1)C1=CN=CN=C1)C1=CC=NC(=C1)C(F)F, NC1=N[C@@](C2=CC=CC(F)=C12)(C1=CC=CC(=C1)C1=CN=CN=C1)C1=CC=NC(=C1)C(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male and female volunteers of non-childbearing potential aged 18 to 55 years
             (inclusive) with suitable veins for cannulation or repeated venipuncture

          -  Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive) and weigh between 50
             kg and 100 kg (inclusive)

          -  Creatinine clearance in the normal range (>80 mL/min estimated according to
             Cockroft-Gault)

          -  Healthy volunteers should have a serum potassium concentration of ≥3.8 mmol/L at
             screening (Visit 1) and on admission to the study centre (Day -1)

          -  Clinically normal findings on physical examination in relation to age, as judged by
             the Investigator

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the healthy volunteer at risk because of participation in
             the study, or influence the results or the healthy volunteer's ability to participate
             in the study

          -  History of psychotic disorder amongst first degree relatives

          -  Significant orthostatic reaction at enrolment as judged by the Investigator

          -  Prolonged QTcF greater than 450 msec or shortened QTcF less than 340 msec or family
             history of long QT syndrome or sudden death

          -  Healthy volunteer is a vegetarian/lactose intolerant (exclusion criterion only
             applicable for healthy volunteers participating in Part 2
Clinical trial NCT01410188 (phase 1/phase 2, status: completed)
Conditions: primary open-angle glaucoma, ocular hypertension
ICD codes: H40.053, H40.051, H40.052, H40.059
Drugs: opa-6566, placebo, latanoprost
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of bilateral primary open-angle glaucoma

          -  diagnosis of ocular hypertension as defined in the protocol

        Exclusion Criteria:

          -  any form of glaucoma other than primary open-angle glaucoma in either eye

          -  other ocular conditions as defined by the protocol
Clinical trial NCT01155336 (phase 1/phase 2, status: terminated)
Conditions: myocardial infarction
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: lovaza®, the placebo contained 1 gram of corn oil in each capsule.
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    only 5 individuals were able to be recruited.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Acute myocardial infarction documented by at least 2 of the following:

               1. Typical symptoms

               2. Abnormal levels of cardiac biomarkers (troponin I or T or CK-MB mass) with at
                  least one determination > 99th percentile or ULN for the laboratory

               3. ECG findings diagnostic of myocardial infarction based on the American College of
                  Cardiology criteria.

          -  Status-post urgent or emergent PCI

          -  Have a Thrombolysis In Myocardial Infarction (TIMI) flow grade = 3 (complete
             perfusion) post PCI.

          -  Have the capacity for informed consent (e.g. without significant dementia or sedation
             from medication)

          -  Ingested 325 mg of chewed aspirin as part of the acute coronary syndrome treatment
             protocol.

        Exclusion Criteria:

          -  No informed consent

          -  Daily aspirin use prior to index hospitalization

          -  Known prior myocardial infarction

          -  Known pregnancy

          -  Known allergy to fish, fish oil, or aspirin

          -  Known active internal or non-superficial bleeding, known bleeding disorder,
             coagulation defect, or thrombocytopenia

          -  Thrombolysis in the past 12 hours

          -  Treatment with a IIbIIIa inhibitor during index hospitalization

          -  Cardiogenic shock or symptomatic hypotension or sitting SBP < 95 mmHg

          -  Severe uncontrolled hypertension (≥180/110) or hypertensive retinopathy

          -  A history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal
             (not hemorrhoidal) or genitourinary bleeding in the past 6 weeks

          -  A history of cerebrovascular attack within two years, or cerebrovascular attack with a
             significant residual neurological deficit

          -  A known arteriovenous malformation or aneurysm

          -  Severe liver insufficiency (ALT ≥ 3 times normal)

          -  Renal insufficiency requiring dialysis

          -  A known diagnosis of vasculitis

          -  Participation in another clinical study

          -  History of malignancy, except subjects who have been disease-free for greater than 10
             years, or whose only malignancy has been basal or squamous cell skin carcinoma

          -  Oral contraceptive use

          -  Daily use of NSAIDs

          -  History of drug or alcohol abuse, or current weekly alcohol consumption >14 units/week
             (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 shot of alcohol)
Clinical trial NCT01811849 (phase 1, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin lispro, insulin lispro, insulin lispro
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age: ≥18 to ≤70 years

          -  Body Mass Index: ≥18 and ≤35 kg/m2

          -  Diagnosed with Type 1 Diabetes Mellitus for at least 1 year

        Exclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Serum C-peptide >1.0 ng/mL

          -  HbA1c >10.0%

          -  History of hypersensitivity to any of the components in the study medication

          -  Treatment with any other investigational drug in the last 30 days before dosing.

          -  Current drug or alcohol abuse, or a history of drug or alcohol abuse which in the
             opinion of the Investigator will impair subject safety, protocol compliance, or
             interpretation of study results. Caffeine, nicotine or alcohol addiction which might
             be expected to result in withdrawal symptoms during the course of a study dosing day
             would fall into this category.